We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Protein-Based Test Improves Prognostic Accuracy for Prostate Cancer

By LabMedica International staff writers
Posted on 27 Oct 2014
Print article
Image: Histopathology of prostatic acinar adenocarcinoma, the most common form of prostate cancer, Gleason pattern 4, from prostate curettings (Photo courtesy of Nephron).
Image: Histopathology of prostatic acinar adenocarcinoma, the most common form of prostate cancer, Gleason pattern 4, from prostate curettings (Photo courtesy of Nephron).
A protein-based biopsy test has been designed to improve the accuracy of prognosis for men diagnosed with prostate cancer and can help identify the aggressiveness of the disease.

The first-of-its-kind test works by measuring the amount of specific protein biomarkers obtained by needle biopsy from regions of prostate tissue where the biomarkers are altered during tumor formation.

The biopsy test called ProMark (Metamark; Cambridge, MA, USA) has been validated in multiple clinical studies totaling more than 1,250 cases, all of which demonstrated the ability to differentiate between aggressive and non-aggressive forms of prostate cancer at early stages of disease. The blinded clinical validation study showed ProMark predicted which patients had low-risk disease with a high sensitivity, thereby helping to identify patients who may be appropriate candidates for active surveillance or in need of aggressive therapy. ProMark uses a novel, automated, quantitative protein-based multiplex imaging platform.

Neal D. Shore, MD, medical director of the Carolina Urologic Research Center (Myrtle Beach, SC, USA), said, “Enhancing risk stratification is especially important with newly diagnosed prostate cancer patients, which can assist with their understanding of treatment options. Adding a proteomic test, in addition to traditional metrics of physical examination, prostate-specific antigen (PSA) test, and histopathology, could improve shared decision making. The ProMark test may provide the healthcare community with additional information to assist distinguishing indolent from aggressive prostate cancer, thus better informing decisions on an appropriate course of treatment or surveillance.”

Shawn Marcell, BA, the CEO of Metamark, said, “ProMark is a valuable tool that will address the urology community's unmet need for having actionable information, by providing an individualized risk assessment to men whose biopsies have indicated disease presence. Metamark has served the urology space exclusively for years, and as such, we understand the unique challenges and uncertainties faced by patients and physicians.”

Related Links:

Metamark 
Carolina Urologic Research Center 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.